NCT04486781View on ClinicalTrials.gov

A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

August 14, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Metastatic Urothelial Carcinoma
Interventions
DRUG

Pembrolizumab + sEphB4-HSA

sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor.

Trial Locations (1)

90403

RECRUITING

Sarcoma Oncology Center, Santa Monica

All Listed Sponsors
lead

Vasgene Therapeutics, Inc

INDUSTRY